NAL ( DrugBank: - )


2 diseases
告示番号疾患名(ページ内リンク)臨床試験数
6パーキンソン病8
299嚢胞性線維症9

6. パーキンソン病


臨床試験数 : 2,307 薬物数 : 2,007 - (DrugBank : 349) / 標的遺伝子数 : 188 - 標的パスウェイ数 : 199
No.TrialIDDate_
enrollment
Date_
registration
Public_titleScientific_titleConditionInterventionPrimary_
sponsor
Secondary_
sponsor
Recruitment_
Status
Inclusion_
agemin
Inclusion_
agemax
Inclusion_
gender
Target_
size
PhaseCountries
1NCT02934919
(ClinicalTrials.gov)
December 201614/10/2016Evaluation of Nalmefene in Impulse Control Disorders in Parkinson's Disease: A Prospective Open Label StudyEvaluation of Nalmefene in Impulse Control Disorders in Parkinson's Disease: A Prospective Open Label StudyImpulse Control Disorders;Parkinson DiseaseDrug: NalmefeneUniversity Hospital, Clermont-FerrandNULLNot yet recruiting18 Years80 YearsBoth30Phase 2France
2EUCTR2011-002901-31-DE
(EUCTR)
08/03/201206/10/2011not applicableA multicentre, double-blind, randomised, placebo controlled study to determine the efficacy and tolerability of OXN PR for the treatment of severe Parkinson’s disease associated pain - A randomised placebo controlled study of OXN PR for severe Parkinson’s disease associated pain Subjects will have idiopathic Parkinson's disease and be suffering from severe PD associated pain.
MedDRA version: 14.1;Level: LLT;Classification code 10013113;Term: Disease Parkinson's;System Organ Class: 100000004852;Therapeutic area: Diseases [C] - Nervous System Diseases [C10]
Trade Name: Targinact 5 mg/2.5 mg prolonged-release tablets
Product Name: oxycodone/naloxone prolonged release tablets 5 mg /2.5 mg
Product Code: OXN 5 mg/2.5 mg PR
INN or Proposed INN: Oxycodone hydrochloride
Other descriptive name: OXYCODONE HYDROCHLORIDE
INN or Proposed INN: Naloxone Hydrochloride Dihydrate
Other descriptive name: NALOXONE HYDROCHLORIDE DIHYDRATE
Trade Name: Targinact 10 mg/5 mg prolonged-release tablets
Product Name: oxycodone/naloxone prolonged release tablets 10 mg /5 mg
Product Code: OXN 10 mg / 5 mg PR
INN or Proposed INN: Oxycodone Hydrochloride
Other descriptive name: OXYCODONE HYDROCHLORIDE
INN or Proposed INN: Naloxone Hydrochloride Dihydrate
Other descriptive name: NALOXONE HYDROCHLORIDE DIHYDRATE
Trade Name: Targinact 20 mg/10 mg prolonged-release tablets
Product Name: oxycodone/naloxone prolonged release tablets 20 mg /10 mg
Product Code: OXN 20 mg / 10 mg PR
INN or Proposed INN: OXYCODONE HYDROCHLORIDE
Other descriptive name: OXYCODONE HYDROCHLORIDE
INN or Proposed INN: NAL
Mundipharma Research GmbH & Co. KGNULLNot RecruitingFemale: yes
Male: yes
210Hungary;Czech Republic;Spain;Germany;United Kingdom
3EUCTR2011-002901-31-HU
(EUCTR)
21/12/201113/10/2011not applicableA multicentre, double-blind, randomised, placebo controlled study to determine the efficacy and tolerability of OXN PR for the treatment of severe Parkinson’s disease associated pain - A randomised placebo controlled study of OXN PR for severe Parkinson’s disease associated pain Subjects will have idiopathic Parkinson's disease and be suffering from severe PD associated pain.
MedDRA version: 14.1;Level: LLT;Classification code 10013113;Term: Disease Parkinson's;System Organ Class: 100000004852;Therapeutic area: Diseases [C] - Nervous System Diseases [C10]
Trade Name: Targinact 5 mg/2.5 mg prolonged-release tablets
Product Name: oxycodone/naloxone prolonged release tablets 5 mg /2.5 mg
Product Code: OXN 5 mg/2.5 mg PR
INN or Proposed INN: Oxycodone hydrochloride
Other descriptive name: OXYCODONE HYDROCHLORIDE
INN or Proposed INN: Naloxone Hydrochloride Dihydrate
Other descriptive name: NALOXONE HYDROCHLORIDE DIHYDRATE
Trade Name: Targinact 10 mg/5 mg prolonged-release tablets
Product Name: oxycodone/naloxone prolonged release tablets 10 mg /5 mg
Product Code: OXN 10 mg / 5 mg PR
INN or Proposed INN: Oxycodone Hydrochloride
Other descriptive name: OXYCODONE HYDROCHLORIDE
INN or Proposed INN: Naloxone Hydrochloride Dihydrate
Other descriptive name: NALOXONE HYDROCHLORIDE DIHYDRATE
Trade Name: Targinact 20 mg/10 mg prolonged-release tablets
Product Name: oxycodone/naloxone prolonged release tablets 20 mg /10 mg
Product Code: OXN 20 mg / 10 mg PR
INN or Proposed INN: OXYCODONE HYDROCHLORIDE
Other descriptive name: OXYCODONE HYDROCHLORIDE
INN or Proposed INN: NAL
Mundipharma Research GmbH & Co. KGNULLNot RecruitingFemale: yes
Male: yes
210Czech Republic;Hungary;Spain;Germany;United Kingdom
4EUCTR2011-002901-31-CZ
(EUCTR)
12/12/201110/10/2011not applicableA multicentre, double-blind, randomised, placebo controlled study to determine the efficacy and tolerability of OXN PR for the treatment of severe Parkinson’s disease associated pain - A randomised placebo controlled study of OXN PR for severe Parkinson’s disease associated pain Subjects will have idiopathic Parkinson's disease and be suffering from severe PD associated pain.
MedDRA version: 14.1;Level: LLT;Classification code 10013113;Term: Disease Parkinson's;System Organ Class: 100000004852;Therapeutic area: Diseases [C] - Nervous System Diseases [C10]
Trade Name: Targinact 5 mg/2.5 mg prolonged-release tablets
Product Name: oxycodone/naloxone prolonged release tablets 5 mg /2.5 mg
Product Code: OXN 5 mg/2.5 mg PR
INN or Proposed INN: Oxycodone hydrochloride
Other descriptive name: OXYCODONE HYDROCHLORIDE
INN or Proposed INN: Naloxone Hydrochloride Dihydrate
Other descriptive name: NALOXONE HYDROCHLORIDE DIHYDRATE
Trade Name: Targinact 10 mg/5 mg prolonged-release tablets
Product Name: oxycodone/naloxone prolonged release tablets 10 mg /5 mg
Product Code: OXN 10 mg / 5 mg PR
INN or Proposed INN: Oxycodone Hydrochloride
Other descriptive name: OXYCODONE HYDROCHLORIDE
INN or Proposed INN: Naloxone Hydrochloride Dihydrate
Other descriptive name: NALOXONE HYDROCHLORIDE DIHYDRATE
Trade Name: Targinact 20 mg/10 mg prolonged-release tablets
Product Name: oxycodone/naloxone prolonged release tablets 20 mg /10 mg
Product Code: OXN 20 mg / 10 mg PR
INN or Proposed INN: OXYCODONE HYDROCHLORIDE
Other descriptive name: OXYCODONE HYDROCHLORIDE
INN or Proposed INN: NAL
Mundipharma Research GmbH & Co. KGNULLNot RecruitingFemale: yes
Male: yes
210Hungary;Czech Republic;Spain;Germany;United Kingdom
5EUCTR2011-002901-31-ES
(EUCTR)
30/11/201105/10/2011not applicableA multicentre, double-blind, randomised, placebo controlled study to determine the efficacy and tolerability of OXN PR for the treatment of severe Parkinson's disease associated pain - A randomised placebo controlled study of OXN PR for severe Parkinson?s disease associated pain Subjects will have idiopathic Parkinson's disease and be suffering from severe PD associated pain.
MedDRA version: 14.0;Level: LLT;Classification code 10013113;Term: Disease Parkinson's;System Organ Class: 10029205 - Nervous system disorders;Therapeutic area: Diseases [C] - Nervous System Diseases [C10]
Trade Name: Targinact 5 mg/2.5 mg prolonged-release tablets
Product Name: oxycodone/naloxone prolonged release tablets 5 mg /2.5 mg
Product Code: OXN 5 mg/2.5 mg PR
INN or Proposed INN: Oxycodone hydrochloride
Other descriptive name: OXYCODONE HYDROCHLORIDE
INN or Proposed INN: Naloxone Hydrochloride Dihydrate
Other descriptive name: NALOXONE HYDROCHLORIDE DIHYDRATE
Trade Name: Targinact 10 mg/5 mg prolonged-release tablets
Product Name: oxycodone/naloxone prolonged release tablets 10 mg /5 mg
Product Code: OXN 10 mg / 5 mg PR
INN or Proposed INN: Oxycodone Hydrochloride
Other descriptive name: OXYCODONE HYDROCHLORIDE
INN or Proposed INN: Naloxone Hydrochloride Dihydrate
Other descriptive name: NALOXONE HYDROCHLORIDE DIHYDRATE
Trade Name: Targinact 20 mg/10 mg prolonged-release tablets
Product Name: oxycodone/naloxone prolonged release tablets 20 mg /10 mg
Product Code: OXN 20 mg / 10 mg PR
INN or Proposed INN: OXYCODO
Mundipharma Research GmbH & Co. KGNULLNot RecruitingFemale: yes
Male: yes
210Phase 3Hungary;Czech Republic;Spain;Germany;United Kingdom
6EUCTR2011-002901-31-GB
(EUCTR)
25/11/201121/09/2011A multicentre, double-blind, randomised, placebo controlled study to determine the efficacy and tolerability of OXN PR for the treatment of severe Parkinson's disease associated painA multicentre, double-blind, randomised, placebo controlled study to determine the efficacy and tolerability of OXN PR for the treatment of severe Parkinson's disease associated pain - Efficacy of OXN PR in severe Parkinson's disease associated pain Subjects will have idiopathic Parkinson's disease and be suffering from severe PD associated pain.
MedDRA version: 14.1;Level: LLT;Classification code 10013113;Term: Disease Parkinson's;System Organ Class: 100000004852;Therapeutic area: Diseases [C] - Nervous System Diseases [C10]
Trade Name: Targinact 5 mg/2.5 mg prolonged-release tablets
Product Name: oxycodone/naloxone prolonged release tablets 5 mg /2.5 mg
Product Code: OXN 5 mg/2.5 mg PR
INN or Proposed INN: Oxycodone hydrochloride
Other descriptive name: Oxycodone hydrochloride
INN or Proposed INN: Naloxone Hydrochloride Dihydrate
Other descriptive name: NALOXONE HYDROCHLORIDE DIHYDRATE
Trade Name: Targinact 10 mg/5 mg prolonged-release tablets
Product Name: oxycodone/naloxone prolonged release tablets 10 mg /5 mg
Product Code: OXN 10 mg / 5 mg PR
INN or Proposed INN: Oxycodone Hydrochloride
Other descriptive name: OXYCODONE HYDROCHLORIDE
INN or Proposed INN: Naloxone Hydrochloride Dihydrate
Other descriptive name: NALOXONE HYDROCHLORIDE DIHYDRATE
Trade Name: Targinact 20 mg/10 mg prolonged-release tablets
Product Name: oxycodone/naloxone prolonged release tablets 20 mg /10 mg
Product Code: OXN 20 mg / 10 mg PR
INN or Proposed INN: OXYCODONE HYDROCHLORIDE
Other descriptive name: OXYCODONE HYDROCHLORIDE
INN or Proposed INN: NAL
Mundipharma Research GmbH & Co. KGNULLNot RecruitingFemale: yes
Male: yes
210Phase 3Hungary;Czech Republic;Spain;Germany;United Kingdom
7NCT01439100
(ClinicalTrials.gov)
October 201121/9/2011A Randomised Placebo Controlled Study of OXN PR for Severe Parkinson's Disease Associated PainParkinson's Disease With Severe PainDrug: Oxycodone/Naloxone Prolonged Release tablets;Drug: PlaceboMundipharma Research GmbH & Co KGNULLCompleted25 YearsN/ABoth172Phase 3Czech Republic;Germany;Hungary;Poland;Romania;Spain;United Kingdom
8NCT01052831
(ClinicalTrials.gov)
November 200915/1/2010Naltrexone for Impulse Control Disorders in Parkinson's DiseaseRandomized, Double-blind, Placebo-controlled Study of Naltrexone for Impulse Control Disorders in Parkinson's DiseaseImpulse Control Disorder;Parkinson DiseaseDrug: Naltrexone;Drug: PlaceboUniversity of PennsylvaniaMichael J. Fox Foundation for Parkinson's ResearchCompleted18 Years85 YearsAll50Phase 4United States

299. 嚢胞性線維症


臨床試験数 : 1,695 薬物数 : 1,527 - (DrugBank : 268) / 標的遺伝子数 : 111 - 標的パスウェイ数 : 174
No.TrialIDDate_
enrollment
Date_
registration
Public_titleScientific_titleConditionInterventionPrimary_
sponsor
Secondary_
sponsor
Recruitment_
Status
Inclusion_
agemin
Inclusion_
agemax
Inclusion_
gender
Target_
size
PhaseCountries
1EUCTR2010-018454-13-DK
(EUCTR)
27/10/201013/08/2010A Phase III, Multicentre, Randomised, Placebo-Controlled, Double Blind Study of the Incidence of Recurring Pulmonary Exacerbations in Cystic Fibrosis Patients using Two Different Doses of Inhaled Nacystelyn®A Phase III, Multicentre, Randomised, Placebo-Controlled, Double Blind Study of the Incidence of Recurring Pulmonary Exacerbations in Cystic Fibrosis Patients using Two Different Doses of Inhaled Nacystelyn® Cystic fibrosis
MedDRA version: 12.1;Level: PT;Classification code 10011762;Term: Cystic fibrosis
Product Name: Nacystelyn®
Product Code: NAL
INN or Proposed INN: L-Lysine-N-acetylcysteinate
Other descriptive name: Nacystelyn®
Product Name: Nacystelyn®
Product Code: NAL
INN or Proposed INN: L-Lysine-N-acetylcysteinate
Other descriptive name: Nacystelyn®
Laboratoires SMB S.A.NULLNot RecruitingFemale: yes
Male: yes
552Phase 3France;Czech Republic;Hungary;Spain;Belgium;Denmark;Germany;United Kingdom;Italy
2EUCTR2010-018454-13-ES
(EUCTR)
06/09/201031/05/2010A Phase III, Multicentre, Randomised, Placebo-Controlled, Double Blind Study of the Incidence of Recurring Pulmonary Exacerbations in Cystic Fibrosis Patients using Two Different Doses of Inhaled Nacystelyn®Estudio de fase III multicéntrico, doble ciego, aleatorizado y controlado con placebo de la incidencia de recurrencia de las exacerbaciones pulmonares en pacientes con fibrosis quística utilizando dos dosis diferentes de Nacystelyn® inhaladoA Phase III, Multicentre, Randomised, Placebo-Controlled, Double Blind Study of the Incidence of Recurring Pulmonary Exacerbations in Cystic Fibrosis Patients using Two Different Doses of Inhaled Nacystelyn®Estudio de fase III multicéntrico, doble ciego, aleatorizado y controlado con placebo de la incidencia de recurrencia de las exacerbaciones pulmonares en pacientes con fibrosis quística utilizando dos dosis diferentes de Nacystelyn® inhalado Cystic fibrosisFibrosis quistica
MedDRA version: 12.1;Level: PT;Classification code 10011762;Term: Cystic fibrosis
Product Name: Nacystelyn®
Product Code: NAL
INN or Proposed INN: L-Lysine- N-acetylcysteinate
Other descriptive name: Nacystelyn®
Product Name: Nacystelyn®
Product Code: NAL
INN or Proposed INN: L-Lysine- N-acetylcysteinate
Other descriptive name: Nacystelyn®
Laboratoires SMB S.A.NULLNot RecruitingFemale: yes
Male: yes
552Phase 3France;Czech Republic;Hungary;Belgium;Spain;Denmark;Germany;United Kingdom;Italy
3EUCTR2010-018454-13-GB
(EUCTR)
01/09/201018/06/2010A Phase III, Multicentre, Randomised, Placebo-Controlled, Double Blind Study of the Incidence of Recurring Pulmonary Exacerbations in Cystic Fibrosis Patients using Two Different Doses of Inhaled Nacystelyn®A Phase III, Multicentre, Randomised, Placebo-Controlled, Double Blind Study of the Incidence of Recurring Pulmonary Exacerbations in Cystic Fibrosis Patients using Two Different Doses of Inhaled Nacystelyn® Cystic fibrosis
MedDRA version: 12.1;Level: PT;Classification code 10011762;Term: Cystic fibrosis
Product Name: Nacystelyn®
Product Code: NAL
INN or Proposed INN: L-Lysine-N-acetylcysteinate
Other descriptive name: Nacystelyn®
Product Name: Nacystelyn®
Product Code: NAL
INN or Proposed INN: L-Lysine-N-acetylcysteinate
Other descriptive name: Nacystelyn®
Laboratoires SMB S.A.NULLNot RecruitingFemale: yes
Male: yes
552Phase 3Hungary;Czech Republic;Germany;United Kingdom;France;Spain;Italy
4EUCTR2010-018454-13-DE
(EUCTR)
31/08/201021/05/2010A Phase III, Multicentre, Randomised, Placebo-Controlled, Double Blind Study of the Incidence of Recurring Pulmonary Exacerbations in Cystic Fibrosis Patients using Two Different Doses of Inhaled Nacystelyn®A Phase III, Multicentre, Randomised, Placebo-Controlled, Double Blind Study of the Incidence of Recurring Pulmonary Exacerbations in Cystic Fibrosis Patients using Two Different Doses of Inhaled Nacystelyn® Cystic fibrosis
MedDRA version: 12.1;Level: PT;Classification code 10011762;Term: Cystic fibrosis
Product Name: Nacystelyn®
Product Code: NAL
INN or Proposed INN: L-Lysine-N-acetylcysteinate
Other descriptive name: Nacystelyn®
Product Name: Nacystelyn®
Product Code: NAL
INN or Proposed INN: L-Lysine-N-acetylcysteinate
Other descriptive name: Nacystelyn®
Laboratoires SMB S.A.NULLNot RecruitingFemale: yes
Male: yes
552Phase 3Hungary;Czech Republic;United Kingdom;Germany;France;Spain;Italy
5EUCTR2010-018454-13-CZ
(EUCTR)
27/08/201021/06/2010A Phase III, Multicentre, Randomised, Placebo-Controlled, Double Blind Study of the Incidence of Recurring Pulmonary Exacerbations in Cystic Fibrosis Patients using Two Different Doses of Inhaled Nacystelyn®A Phase III, Multicentre, Randomised, Placebo-Controlled, Double Blind Study of the Incidence of Recurring Pulmonary Exacerbations in Cystic Fibrosis Patients using Two Different Doses of Inhaled Nacystelyn® Cystic fibrosis
MedDRA version: 12.1;Level: PT;Classification code 10011762;Term: Cystic fibrosis
Product Name: Nacystelyn®
Product Code: NAL
INN or Proposed INN: L-Lysine-N-acetylcysteinate
Other descriptive name: Nacystelyn®
Product Name: Nacystelyn®
Product Code: NAL
INN or Proposed INN: L-Lysine-N-acetylcysteinate
Other descriptive name: Nacystelyn®
Laboratoires SMB S.A.NULLNot RecruitingFemale: yes
Male: yes
552Phase 3Hungary;United Kingdom;Germany;Czech Republic;France;Spain;Italy
6EUCTR2010-018454-13-HU
(EUCTR)
17/08/201017/06/2010A Phase III, Multicentre, Randomised, Placebo-Controlled, Double Blind Study of the Incidence of Recurring Pulmonary Exacerbations in Cystic Fibrosis Patients using Two Different Doses of Inhaled Nacystelyn®A Phase III, Multicentre, Randomised, Placebo-Controlled, Double Blind Study of the Incidence of Recurring Pulmonary Exacerbations in Cystic Fibrosis Patients using Two Different Doses of Inhaled Nacystelyn® Cystic fibrosis
MedDRA version: 12.1;Level: PT;Classification code 10011762;Term: Cystic fibrosis
Product Name: Nacystelyn®
Product Code: NAL
INN or Proposed INN: L-Lysine-N-acetylcysteinate
Other descriptive name: Nacystelyn®
Product Name: Nacystelyn®
Product Code: NAL
INN or Proposed INN: L-Lysine-N-acetylcysteinate
Other descriptive name: Nacystelyn®
Laboratoires SMB S.A.NULLNot RecruitingFemale: yes
Male: yes
552Phase 3Hungary;Czech Republic;United Kingdom;Germany;France;Spain;Italy
7EUCTR2010-018454-13-FR
(EUCTR)
10/08/201028/05/2010A Phase III, Multicentre, Randomised, Placebo-Controlled, Double Blind Study of the Incidence of Recurring Pulmonary Exacerbations in Cystic Fibrosis Patients using Two Different Doses of Inhaled Nacystelyn®A Phase III, Multicentre, Randomised, Placebo-Controlled, Double Blind Study of the Incidence of Recurring Pulmonary Exacerbations in Cystic Fibrosis Patients using Two Different Doses of Inhaled Nacystelyn® Cystic fibrosis
MedDRA version: 12.1;Level: PT;Classification code 10011762;Term: Cystic fibrosis
Product Name: Nacystelyn®
Product Code: NAL
INN or Proposed INN: L-Lysine-N-acetylcysteinate
Other descriptive name: Nacystelyn®
Product Name: Nacystelyn®
Product Code: NAL
INN or Proposed INN: L-Lysine-N-acetylcysteinate
Other descriptive name: Nacystelyn®
Laboratoires SMB S.A.NULLNot RecruitingFemale: yes
Male: yes
552Phase 3France;Czech Republic;Hungary;Spain;Belgium;Denmark;Germany;United Kingdom;Italy
8EUCTR2010-018454-13-IT
(EUCTR)
15/07/201015/06/2010A Phase III, Multicentre, Randomised, Placebo-Controlled, Double Blind Study of the Incidence of Recurring Pulmonary Exacerbations in Cystic Fibrosis Patients using Two Different Doses of Inhaled Nacystelyn - NDA Phase III, Multicentre, Randomised, Placebo-Controlled, Double Blind Study of the Incidence of Recurring Pulmonary Exacerbations in Cystic Fibrosis Patients using Two Different Doses of Inhaled Nacystelyn - ND Cystic fibrosis
MedDRA version: 9.1;Level: PT;Classification code 10011762
Product Name: Nacystelyn
Product Code: NAL
INN or Proposed INN: L-Lysine N acetylcysteinate
Product Name: Nacystelyn
Product Code: NAL
INN or Proposed INN: L-Lysine N-acetylcysteinate
LABORATOIRES SMB S.A.NULLNot RecruitingFemale: yes
Male: yes
552Phase 3Hungary;Czech Republic;United Kingdom;Germany;France;Spain;Italy
9EUCTR2010-018454-13-BE
(EUCTR)
25/05/2010A Phase III, Multicentre, Randomised, Placebo-Controlled, Double Blind Study of the Incidence of Recurring Pulmonary Exacerbations in Cystic Fibrosis Patients using Two Different Doses of Inhaled Nacystelyn®A Phase III, Multicentre, Randomised, Placebo-Controlled, Double Blind Study of the Incidence of Recurring Pulmonary Exacerbations in Cystic Fibrosis Patients using Two Different Doses of Inhaled Nacystelyn® Cystic fibrosis
MedDRA version: 12.1;Level: PT;Classification code 10011762;Term: Cystic fibrosis
Product Name: Nacystelyn®
Product Code: NAL
INN or Proposed INN: L-Lysine-N-acetyl-L-cysteinate
Other descriptive name: Nacystelyn®
Product Name: Nacystelyn®
Product Code: NAL
INN or Proposed INN: L-Lysine-N-acetyl-L-cysteinate
Other descriptive name: Nacystelyn®
Laboratoires SMB S.A.NULLNot RecruitingFemale: yes
Male: yes
552Phase 3France;Czech Republic;Hungary;Spain;Belgium;Denmark;Germany;United Kingdom;Italy